Abstract
The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Volume: 22 Issue: 11
Author(s): Viana M. Suárez, Nelson S. Vispo and Oliberto S. Ramos*
Affiliation:
- Department of Pharmacology, School of Biological Sciences, Universidad de Concepcion, Concepcion,Chile
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Abstract: The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Export Options
About this article
Cite this article as:
Suárez M. Viana, Vispo S. Nelson and Ramos S. Oliberto *, Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier, Current Pharmaceutical Biotechnology 2021; 22 (11) . https://dx.doi.org/10.2174/1389201022666210104115224
DOI https://dx.doi.org/10.2174/1389201022666210104115224 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Current Signal Transduction Therapy Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions
Current Topics in Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Psychiatry Reviews Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases
Current Medicinal Chemistry The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration
Current Molecular Medicine Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry Nanomedicine
Current Nanoscience Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage
Current Topics in Medicinal Chemistry Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders